Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
English
日本語
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Primary tabs
View
(active tab)
Stallergenes
May 21, 2018
After 11 long years Allergy sees a glimmer of hope
April 11, 2016
Interview – Allergy Therapeutics sniffs out second chance
April 02, 2014
And the winner is Stallergenes... for now
March 18, 2014
Circassia emerges as one of the UK’s most valuable life science companies
December 13, 2013
Stallergenes and ALK-Abelló take a step closer to the US market
December 10, 2013
EP Vantage interview – Stallergenes poised to take first US steps
March 08, 2012
Hay fever vaccines entering new season of innovation
March 05, 2012
Event – Meda hoping for summer success with hay fever drug
October 29, 2010
New majority investor for Stallergenes could spell good news
October 22, 2010
EP Vantage Interview - Stallergenes sets huge goal for US market
April 21, 2010
Positive US data for Stallergenes raise hopes of partnering deal
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 31, 2019
Vantage Pharma, Biotech & Medtech Half-Year Review 2019
February 26, 2019
Vantage Pharma, Biotech and Medtech 2018 in Review
Editor's Picks
October 22, 2019
Shock revelation sees Biogen erase its aducanumab losses
October 22, 2019
Vertex’s double cystic fibrosis surprise
October 23, 2019
Bristol might play a role in front-line lung cancer after all
October 23, 2019
Bloated on arrival? Biotech's weightiest new issues
October 14, 2019
Uncovering biopharma’s hidden treasures
